Fig. 5
From: Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer
HELA-Exos induce intratumoral accumulation of cDC1s and CD8 + T cells. Balb/c mice with orthotopic breast cancer were sacrificed at day 30 after treatment initiation. Tumor tissues and draining lymph node immune infiltrates were analyzed by IF, flow cytometry and IHC. A Tumor tissue- and draining lymph node-infiltrating cDC1s were detected by IF. Blue: DAPI; Green: CD11c; Red: CD103. Scale bar, 25 μm. B Gating strategy for the analysis of CD11c+ DCs; the expression of CD103, CD11b, H-2Kd/H-2Dd (MHC-I), and I-Ab (MHC-II) on DCs was measured using flow cytometry. C The percentages of tumor-infiltrating CD4+ or CD8+ T cells were measured using flow cytometry. D to F Tumor-infiltrating CD8+ T cells were analyzed for the expression of the cytotoxicity markers granzyme B and perforin, the activation marker CD69 and the immunosuppressive marker PD1. The data are presented as the mean ± SD; n = 6. t test and one-way ANOVA were performed for statistical analysis (****: P < 0.0001; **: P < 0.01; ns: P > 0.05). Scale bar, 25 μm. IF: immunofluorescence; IHC: immunohistochemistry